



## **Indag Rubber Limited**

**Regd. Office :** Khemka House, 11, Community Centre, Saket, New Delhi - 110017, India  
Phone : 26963172-73, 26961211, 26863310, 41664818, 41664043, Fax : 011- 26856350  
E-mail : info@indagrubber.com, Website: www.indagrubber.com, **CIN-L74899DL1978PLC009038**

**Works :** Village Jhiriwala, Tehsil, Nalagarh, Distt. Solan, Himachal Pradesh - 174101, India  
Phone : 09736000123

**June 23, 2020**

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai-400001

**(Company code-1321)**

**(Scrip code-509162)**

**Subject: Newspaper clipping of notice published in newspaper intimating the date of the Board Meeting.**

Dear Sir,

Enclosed herewith please find newspaper clipping of notice published in the Business Standard **(both Hindi & English)** on June 23, 2020 for the intimation of the date of Board Meeting to be held on Friday, 26<sup>th</sup> June, 2020.

This is for your information and records please.

Yours faithfully,  
For **Indag Rubber Limited**

**SD/-**  
**Manali D. Bijlani**  
**Company Secretary**


(Contact Details: +91-9811743984)

*(the document could not be physically signed since the employees are working from home)*

# Equal access next hurdle

The 2nd of a two-part series examines challenges linked to IPR and monopoly once Covid vaccine is created

GEETIKA SRIVASTAVA  
New Delhi, 22 June



Even if a vaccine is created and manufactured within the expected timeframe, it may not mean an end to Covid-induced misery for all. Equal access to the vaccine could be a major challenge, according to experts. Experience during the Swine Flu pandemic shows how.

When in 2009 the World Health Organization (WHO) declared the Swine Flu influenza a pandemic, big pharmaceutical firms invested huge sums in research and developed a vaccine, which they then patented. The resultant monopoly over its formulation led to the highest bidders – developed nations such as the US, Canada, and Australia – placing large orders and stockpiling the product. Low and middle-income nations faced huge shortages.

This sparked a row around equitable access to vaccines and how intellectual property regime (IPR) may have resulted in such disparity. Indonesia, for instance, had earlier refused to share H5N1 virus strains with the world, citing unfairness of sharing resources only to have a developed country monopolise a vaccine.

Efforts to produce a legal framework to bridge this gap have only started to gain traction now. The European Union (EU) took charge at the WHO's Health Assembly in May to introduce provisions regarding voluntary pooling of patents, and the 'Access to Covid-19 Tools Accelerator' through which countries can share technical knowhow and resources.

"The idea behind this is that the knowhow can be owned collectively and then further licensed to all states so they can produce vaccines," says Kashish Aneja, a lawyer working with O'Neill Institute for National and Global Health Law in Washington.

While this was supported by some countries such as the US chose to "disassociate" themselves from certain parts of the resolution which reference the Doha Declaration. According to Doha Declaration, governments could overrule intellectual property in case of a public emergency. The US also steered clear of contributing to an \$8-billion fund to ensure equal access to vaccines for the world.

This development is worrisome for other countries since the US, with a large number of ongoing projects, has a high chance of creating a vaccine. According to international law, any vaccine which is created becomes the property of the sovereign, who has the right to leverage its distribution. Australia, for instance, prohibited exports of Swine

## THEN

■ **During the Swine flu pandemic**, developed nations such as the US, Canada and Australia pre-booked large quantities of the vaccine

■ **Low- and middle-income countries** fell short

■ **Australia prohibit manufacturers** from exporting the vaccine until its own needs were met

■ **Canada refused to donate** vaccines citing shortages of its own

## NOW

■ **Indian biotech firms** such as Panacea, Serum Institute, and Bharat Biotech are collaborating with international institutions to ensure availability

■ **Gilead Sciences rescinded its** 'orphan drug' status for remdesivir after public backlash

■ **Sanofi altered its stance** after saying that the US had the "right to the largest pre-order" of its vaccine

Flu vaccines in 2009.

The same vaccine could have been manufactured in India and other developing countries by applying a provision known as voluntary licensing. However, experts say pharma giants remained sceptical of IPR regimes in developing nations, fearing violations. "The inability of developing countries to negotiate a licensing fee, lack of better returns, and political concerns could all have played a role here," says Aditi Verma Thakur, partner at IndusLaw.

"However, businesses now realise that if they license a vaccine to a firm here and some other firm violates their patent rights, they can enforce their rights in an easier manner," adds Aditya Gupta, attorney of law at IRA law.

Currently, Indian biotech firms such as Panacea, Serum Institute and Bharat Biotech are playing a key role in trying to ensure availability of vaccines by collaborating with firms abroad. Serum Institute along with AstraZeneca has ensured supply of vaccines to India and other low-income countries.

International biotech companies, however, still have a reason to be wary as India is prone to compulsory licensing – a mechanism through which governments can manufacture a patented drug without the permission of the patent holder and sell it at an affordable price. This often puts it under pressure from countries such as the US, which claim exploitation of their firms and threaten sanctions against those countries which feature on their '301 List'.

Meanwhile, companies are being careful with their strategy as they're nervous about public backlash. Gilead

Sciences asked the USFDA to rescind the orphan drug status for its drug Remdesivir, which is being touted as a potential Covid-19 cure, after outcry from public, since the tag comes with many years of market exclusivity. AbbVie noted that it won't enforce patent rights for its drug Kaletra, another candidate for a Covid-19 cure. French firm Sanofi altered its stance after initially announcing that the US had the "right to the largest pre-order" of the vaccine, after outrage from the public as well as the French government.

Despite efforts, a framework which makes it obligatory – not just a choice – for countries to share resources is still missing. Even though some legal instruments mention an individual's right to health, it still remains a right which is considered responsibility of a nation to enforce in its own land, without making it an obligation for the international community. During the Swine Flu pandemic, developed nations did not resort to donating vaccines until they realised that a single dose of vaccine would be enough to cover their citizens and what they had was much more than they needed.

Since pharma giants had monopolies over prevention and their primary incentive was wealth, not public good, it was reason enough for them to supply to those who paid the most, point out analysts.

The IPR framework has always been caught in a research-versus-public benefit debate. The jury's still out on whether Covid-19 will be able to change the regime.

Series concluded

## GOVERNMENT OF MEGHALAYA O/o CHIEF ENGINEER, PWD (ROADS)

NATIONAL HIGHWAY:: MEGHALAYA, SHILLONG  
No. PW/CE/NH/WB/10/2019/47 Dated : 18-06-2020

### PRESS NOTICE

The Chief Engineer (NH), PWD (Roads), Meghalaya on behalf of the Governor of Meghalaya invite Bids for the Up-gradation / Improvement of 2 (Two) Packages Road Works (West and East Meghalaya) to be implemented under the World Bank funded Meghalaya Integrated Transport Project (MITP).

1. Up-gradation / Improvement of Rongjeng Mangsang Adokgre (44th to 55th Km) Ildeka 'Kong to A' Dokgre (L=10 Km).
2. Up-gradation / Improvement of Umling Patharkmah Road (L=31.09 Km).

Interested bidders may check the website <https://meghalayatenders.gov.in> from 24<sup>th</sup> June, 2020 onwards or may also contact the authority mentioned below during office hours.

Sd/-  
Chief Engineer (NH), PWD (Roads)  
Lower Lachumiere  
Shillong – 793001  
Meghalaya

M.I.P.R. No : 316  
Dated : 19-06-2020 Email : [cenhwmbtp@gmail.com](mailto:cenhwmbtp@gmail.com)

## AUROBINDO PHARMA LIMITED

(CIN - L24239TG1986PLC015190)  
Regd. Office: Plot No.2, Maltrivihar, Ameerpet, Hyderabad – 500038.  
Tel No. +91 40 23736370 Fax No. +9140 23747340  
E-mail: [info@aurobindo.com](mailto:info@aurobindo.com) Website: [www.aurobindo.com](http://www.aurobindo.com)

### NOTICE

(For the kind attention of Shareholders of the Company)  
Transfer of Equity Shares of the Company to Investors Education and Protection Fund

In terms of Section 124(6) of the Companies Act, 2013 (the "Act") read with Investors Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 (the "Rules"), the Company is required to transfer the equity shares in respect of which dividend remains unpaid or unclaimed for seven consecutive years to Investors Education and Protection Fund (IEPF) Authority.

A list of such shareholders, who have not encashed their dividends for seven consecutive years from the final dividend declared by the Company in the year 2012-13 and whose shares are therefore liable for transfer to the IEPF account, is displayed on the website of the Company - [www.aurobindo.com](http://www.aurobindo.com).

As per the said Rules, the Company has sent individual communication to the concerned shareholders whose shares are liable to be transferred to IEPF account for taking appropriate action by submitting requisite documents to claim the unclaimed dividend amount(s) by 31<sup>st</sup> August 2020. In the absence of receipt of a valid claim from the concerned shareholder, the Company would proceed to transfer the said unclaimed dividend and corresponding shares to IEPF account without further notice. All future benefits including dividends arising on such shares would also be transferred to IEPF.

Please note that no claim shall lie against the Company in respect of unclaimed dividend amounts and shares transferred to IEPF pursuant to the said rules. Shareholders can claim shares and dividend transferred to IEPF by complying due procedure given in the Rules, details of which are also available at [www.iepf.gov.in](http://www.iepf.gov.in).

For any information / clarification on the matter, the concerned shareholder may write to the Company at [ig@aurobindo.com](mailto:ig@aurobindo.com) or contact the Company's Registrar and Share Transfer Agent - M/s KFin Technologies Pvt. Ltd., Selenium Tower-B, Plot 31-32, Gachibowli, Financial District, Nanakramguda, Hyderabad – 500032. Tel No.: 040-67162222, Fax No.: 040-233001153, email: [einward.ris@kfinotech.com](mailto:einward.ris@kfinotech.com).

For Aurobindo Pharma Limited

Sd/-  
B. Adi Reddy  
Company Secretary  
Place : Hyderabad  
Date : 18.06.2020

**SITI NETWORKS LIMITED**

Regd. Office: Unit No. 38, 1<sup>st</sup> Floor, Madhu Industrial Estate, Pandurang Budhkar Marg, Worli, Mumbai 400013  
Tel.: +91 22 43605555 E-mail: [csandlegal@siti.esselgroup.com](mailto:csandlegal@siti.esselgroup.com)  
CIN: L64200MH2006PLC160733 Website: [www.sitinetworks.com](http://www.sitinetworks.com)

**NOTICE**

Pursuant to Regulation 47 read with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, notice is hereby given that a meeting of the Board of Directors of the Company will be held on Monday, the 29<sup>th</sup> day of June, 2020, inter-alia to consider, approve and take on record the Audited Financial Results of the Company both on standalone and consolidated basis for the 4<sup>th</sup> quarter and financial year ended on March 31, 2020. The information contained in this notice is also available on the website of the Company i.e. [www.sitinetworks.com](http://www.sitinetworks.com) and the website of the Stock Exchanges where the Company's shares are listed i.e. BSE Limited ([www.bseindia.com](http://www.bseindia.com)) and the National Stock Exchange of India Limited ([www.nseindia.com](http://www.nseindia.com)).

For Siti Networks Limited  
Suresh Kumar  
Company Secretary  
M.No. ACS 14390

Place : Delhi  
Date : 22.06.2020

**THE ANDHRA SUGARS LIMITED**

Regd. Office : Venkatarayapuram, TANUKU - 534 215  
West Godavari District, Andhra Pradesh, India.  
Phone : +91 -8819-224911 to 917.  
E-mail : [info.trnk@theandhrasugars.com](mailto:info.trnk@theandhrasugars.com), [investors@theandhrasugars.com](mailto:investors@theandhrasugars.com)  
Website: [www.theandhrasugars.com](http://www.theandhrasugars.com)  
CIN: L15420AP1947PLC000326

## NOTICE

Notice is hereby given that in compliance with the Provisions of Investor Education and Protection Fund Authority (Accounting Audit, Transfer and Refund) Rules ("Rules"), 2016 and Section 124(6) of the Companies Act, 2013, which came into effect from 7<sup>th</sup> September, 2016, the Company is mandated to transfer all such shares in the name of Investor Education and Protection Fund (IEPF) Suspense Account in respect of which dividends has not been paid or claimed for seven consecutive years (2012-13 to 2018-19)

Notice is further given that in accordance with the provisions of the Rules, individual notices have already been sent to respective Shareholders at their latest available addresses in the Company inter alia providing the details of shares being transferred to IEPF suspense Account.

The concerned Shareholders are requested to claim the unpaid/unclaimed dividend amounts with full Bank account particulars as intimated individually failing which their shares shall be transferred to IEPF suspense account.

In case the concerned Shareholders wish to claim the shares after transfer to IEPF Suspense Account, a separate Application can be made to the IEPF Authority, in form IEPF-5, as prescribed under the Rules and the same is available at IEPF website i.e., [www.iepf.gov.in](http://www.iepf.gov.in).

For further information/request to claim the Unpaid/Unclaimed Dividend(s), the concerned Shareholders may contact the Company at Regd. Office: Venkatarayapuram, TANUKU - 534215, Andhra Pradesh.

For THE ANDHRA SUGARS LIMITED

M. PALACHANDRA  
Company Secretary  
VENKATARAYAPURAM  
22.06.2020.

**NMDC Limited**  
(A Government of India Enterprise)  
'Khanij Bhavan', 10-3-311/A, Castle Hills, Masab Tank, Hyderabad - 500 028, Telangana, India. CIN: L13100TG1955G001674

**Empanelment of Transaction Advisors, Legal, Tax & Accounting and Technical Consultants**

Proposals are invited for empanelment of the above consultants for Mergers and Acquisitions and expansion of business in India and Abroad.

The detailed RFE Document can be viewed and / or downloaded from NMDC's website [www.nmdc.co.in](http://www.nmdc.co.in) & Central Procurement Portal [www.eprocure.gov.in](http://www.eprocure.gov.in) from 23-06-2020 to 31-08-2020.

Bidders on regular basis are required to visit the NMDC's website for corrigendum, if any, at a future date. Last date of submission 31-08-2020 at 13:00 hours (IST).  
Email id: [bdpcemp@nmdc.co.in](mailto:bdpcemp@nmdc.co.in)

Deputy General Manager (NMDC Global)

हर एक काम देश के नाम      हुस्पाली हुसदा

**INDAG RUBBER LIMITED**  
CIN: L74899DL1978PLC009038  
Regd. Office: Khemka House, 11 Community Centre, Saket, New Delhi - 110017  
Email: [info@indagrubber.com](mailto:info@indagrubber.com); Website: [www.indagrubber.com](http://www.indagrubber.com); Phone: 011-26963172-73

**NOTICE**

Pursuant to Regulation 29 and Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 notice is hereby given that the meeting of the Board of Directors of the Company is scheduled to be held on Friday, June 26, 2020 to consider, inter-alia, audited financial results for the quarter and year ended March 31, 2020. Further, in pursuance of SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window was closed on April 01, 2020 and would remain closed till June 28, 2020 (both days inclusive).

By order of the Board  
For Indag Rubber Limited  
Sd/-  
Company Secretary

Date: June 22, 2020  
Place: New Delhi

**OLYMPIC CARDS LIMITED**  
Regd. Office: No.195, N.S.C. Bose Road, Chennai-600001  
CIN: L69931TN1992PLC022521; Phone No. 844 42921000/1017  
E-mail: [office@olympiccards.com](mailto:office@olympiccards.com); Website: [www.olympiccards.com](http://www.olympiccards.com)

**NOTICE**

NOTICE is hereby given Pursuant to the Regulation 29 read with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 that a meeting of the Board of Directors of the Company will be held at 11.00 a.m on Tuesday, June 30, 2020 at the Registered Office of the Company at No.195, N.S.C. Bose Road, Chennai-600001 by video conference to consider, inter-alia, the Annual Audited Financial Results for the quarter/year ended March 31, 2020. This information is also available on the Company's Website at [www.olympiccards.com](http://www.olympiccards.com) and Bombay Stock Exchange at [www.bseindia.com](http://www.bseindia.com).

For Olympic Cards Limited,  
Sd/-  
K. Rafeeq Ahmed  
Company Secretary & Compliance Officer  
Membership No. F3637/Mobile No. 9840174388.  
Place : Chennai  
Date : 20-06-2020

## Business Standard DELHI EDITION

Printed and Published by Nandan Singh Rawat on behalf of Business Standard Private Limited and printed at The Indian Express (P) Ltd. A-8, Sector-7, Noida, Gautam Budh Nagar-201301 and published at Nehru House, 4 Bahadur Shah Zafar Marg, New Delhi 110002

Editor : Shyamal Majumdar

RNI NO. 57376/1994

Readers should write their feedback at [feedback@bsmail.in](mailto:feedback@bsmail.in)  
Ph. 011-23720202, Fax : +91-11-23720201

For Subscription and Circulation enquiries please contact:  
Ms. Mansi Singh  
Head-Customer Relations  
Business Standard Private Limited,  
H/4 & I/3, Building H, Paragon Centre, Opp. Birla Centurion, P.B. Marg, Worli, Mumbai - 400013  
E-mail: [subs\\_bs@bsmail.in](mailto:subs_bs@bsmail.in) "or sms, SUB BS to 57007"

**DISCLAIMER** News reports and feature articles in Business Standard seek to present an unbiased picture of developments in the markets, the corporate world and the government. Actual developments can turn out to be different owing to circumstances beyond Business Standard's control and knowledge. Business Standard does not take any responsibility for investment or business decisions taken by readers on the basis of reports and articles published in the newspaper. Readers are expected to form their own judgement. Business Standard does not associate itself with or stand by the contents of any of the advertisements accepted in good faith and published by it. Any claim related to the advertisements should be directed to the advertisers concerned.

Unless explicitly stated otherwise, all rights reserved by M/s Business Standard Pvt. Ltd. Any printing, publication, reproduction, transmission or dissemination of the contents, in any form or by any means, is prohibited without the prior written consent of M/s Business Standard Pvt. Ltd. Any such prohibited and unauthorised act by any person/legal entity shall invite civil and criminal liabilities.

**No Air Surcharge**

**Grandeur Products Limited**  
CIN: L15500TG1983PLC110115  
Registered Office: H. No. 1-52-192, 3rd Floor, Dwaraka Avenue, Kavuri Hills, Madhapur, Hyderabad, Telangana-500033  
Tel: 040-48526655  
E-mail: [info@grandeurproducts.com](mailto:info@grandeurproducts.com)  
Website: [www.grandeurproducts.com](http://www.grandeurproducts.com)

**NOTICE**

Pursuant to Regulation 47 read with Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Notice is hereby given that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, 30<sup>th</sup> day of June, 2020, to consider inter-alia and take on record the Audited Financial Results (Standalone and Consolidated) of the Company for the fourth quarter and financial year ended 31<sup>st</sup> March, 2020.

Further, the trading window for dealing in the securities of the Company has already been closed from 1<sup>st</sup> April, 2020 and will continue to be closed till 2<sup>nd</sup> July, 2020. All insiders and connected persons (including their dependents and immediate relatives), for further details, please refer to the below mentioned URL:  
<http://www.bseindia.com/stock-share-price/grandeur-products-ltd/gpl/539235/>

For GRANDEUR PRODUCTS LIMITED  
Sd/-  
Vijay Kumar Deshpande  
Place : Hyderabad (Whole Time Director)  
Date : 22-06-2020      DIN : 06991267

**JTEKT**  
**JTEKT INDIA LIMITED**  
(Formerly known as Sona Koyo Steering Systems Limited)  
(CIN - L29113DL1984PLC018415)  
Regd. Office: UGF-6, Indraprastha, 21, Barakhamba Road, New Delhi 110001.  
Tel. No. : 011-23311924, 23327205; E-mail: [investorgrievance@jtekt.co.in](mailto:investorgrievance@jtekt.co.in); Website: [www.jtekt.co.in](http://www.jtekt.co.in)

**STATEMENT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2020**

S. No.	Particulars	Standalone (₹ in lakhs, except per equity share data)					Consolidated (₹ in lakhs, except per equity share data)				
		Quarter ended		Year ended		Quarter ended		Year ended			
		31.03.2020	31.12.2019	31.03.2019	31.03.2020	31.03.2019	31.03.2020	31.12.2019	31.03.2019	31.03.2020	31.03.2019
		<b>Audited</b>	<b>Unaudited</b>	<b>Audited</b>	<b>Audited</b>	<b>Audited</b>	<b>Audited</b>	<b>Audited</b>	<b>Audited</b>	<b>Audited</b>	<b>Audited</b>
1.	Total income	37,241.16	37,042.89	48,379.27	1,54,189.26	1,78,566.74	36,700.51	36,603.55	47,829.35	1,51,935.24	1,76,560.99
2.	Net profit for the period before tax (before exceptional items)	757.64	448.30	3,905.03	3,264.08	10,729.87	1,167.75	670.71	4,399.63	4,296.16	12,178.66
3.	Net profit for the period before tax (after exceptional items)	757.64	448.30	3,905.03	3,264.08	10,729.87	1,167.75	670.71	4,399.63	4,296.16	12,178.66
4.	Net profit for the period after tax (after exceptional items)	695.29	460.21	2,412.26	2,750.62	6,856.39	1,062.12	632.14	2,729.93	3,512.16	7,826.16
5.	Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	669.73	397.51	2,336.86	2,528.83	6,844.37	1,022.31	570.22	2,654.61	3,278.45	7,817.08
6.	Paid up equity share capital (Face value of ₹ 1/- per share)	2,444.80	2,444.80	2,444.80	2,444.80	2,444.80	2,444.80	2,444.80	2,444.80	2,444.80	2,444.80
7.	Other equity as shown in the Audited Balance Sheet (excluding revaluation reserve)	-	-	-	54,935.07	54,879.35	-	-	-	57,118.33	56,845.85
8.	Earnings Per Share (EPS) (Face value of ₹ 1/- per share) (not-annualised for the quarter)										
	(a) Basic	0.28	0.19	0.99	1.13	2.80	0.37	0.22	1.05	1.24	2.98
	(b) Diluted	0.28	0.19	0.99	1.13	2.80	0.37	0.22	1.05	1.24	2.98

**Notes :**

1. The above Statement of Audited Standalone and Consolidated Financial Results for the quarter and year ended 31 March 2020, were reviewed by the Audit Committee at their meeting held on 19 June 2020 and approved by the Board of Directors at their meeting held on 22 June 2020. The said results along with the audit report of the Statutory Auditors are available on the BSE Limited ('BSE') website ([URL: www.bseindia.com](http://www.bseindia.com)), the National Stock Exchange of India Limited ('NSE') website ([URL: www.nseindia.com](http://www.nseindia.com)) and on the Company's website ([URL: www.jtekt.co.in](http://www.jtekt.co.in)).
2. The Board at its meeting held on 22 June 2020 considered and recommended a final dividend @ 35% i.e. Rs. 0.35 per equity share of Rs. 1.00 each for the financial year 2019-20. The dates of the Book Closure for the entitlement of such dividend and Annual General Meeting shall be decided and informed in due course of time.

For and on behalf of the Board of Directors of  
JTEKT India Limited  
(formerly known as Sona Koyo Steering Systems Limited)  
Akihiko Kawano  
Managing Director

Place : Gurugram  
Date : 22.06.2020

